Drug intelligence / Profile preview

AL137

Development stage: Preclinical
Lead developer: Alector
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous

Overview

AL137 is a monoclonal antibody candidate developed by Alector, currently in the preclinical stage of development. It is designed to target amyloid-beta (Aβ) for the treatment of Alzheimer's disease. As part of Alector's immuno-neurology portfolio, the program aims to utilize the immune system to facilitate the clearance of amyloid plaques from the brain. While specific mechanistic details distinguishing it from other Aβ-targeting antibodies have not been extensively disclosed, it is categorized within Alector's pipeline as an amyloid-beta antibody (Aβ-Ab).

Targets

pGlu-3 Aβ (Pyroglutamate-3 amyloid-beta peptide)TFRC (Transferrin Receptor)

Beyond the preview

Go deeper on AL137.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AL137.

Explore the full profile